RHEUMATOID ARTHRITIS: CURRENT PHARMACOLOGICAL TREATMENT
DOI:
https://doi.org/10.31435/ijitss.2(50).2026.5628Keywords:
Rheumatoid Arthritis, Treatment, Pathophysiology, DmardsAbstract
Background: Rheumatoid arthritis (RA) is a systemic, chronic autoimmune disease that primarily affects the joints, leading to pain, swelling, stiffness, and fatigue. If left untreated, the disease may result in progressive joint destruction and deformity, long-term disability, and increased mortality.
Aim: The aim of this article is to provide a comprehensive and up-to-date overview of the current understanding of pharmacological treatment approaches for rheumatoid arthritis.
Methods: A narrative review was conducted using the PubMed, Scopus, and Google Scholar databases. The review included original research articles, systematic reviews, and clinical guidelines, published in English between 2018 and 2025, with particular emphasis on evidence from 2021 to 2025. Results: Analysis of current original research articles, systematic reviews, and clinical guidelines shows that pharmacological treatment of rheumatoid arthritis effectively controls disease activity, reduces pain and inflammation, and slows the progression of joint damage.
Conclusions: Pharmacological therapy is key to the treatment of rheumatoid arthritis. For optimal results, therapy should be individualized, taking into account disease activity, other health problems, and drug safety. New biological and targeted synthetic drugs have substantially improved the management of rheumatoid arthritis. However, further research is needed to assess the long-term safety of these therapies and to develop safer and more effective treatment options.
References
Bonfiglioli, K. R., de Medeiros Ribeiro, A. C., Carnieletto, A. P., Pereira, I., Domiciano, D. S., da Silva, H. C., Pugliesi, A., Pereira, L. R., Guimarães, M. F. R., Giorgi, R. D. N., Reis, A. P. M. G., Brenol, C. V., Louzada-Júnior, P., da Cunha Sauma, M. F. L., Radominski, S. C., da Mota, L. M. H., & da Rocha Castelar-Pinheiro, G. (2023). Extra-articular manifestations of rheumatoid arthritis remain a major challenge: Data from a large, multicentric cohort. Advances in Rheumatology, 63(1), Article 34. https://doi.org/10.1186/s42358-023-00318-y
Almutairi, K. B., Nossent, J. C., Preen, D. B., Keen, H. I., & Inderjeeth, C. A. (2021). The prevalence of rheumatoid arthritis: A systematic review of population-based studies. The Journal of Rheumatology, 48(5), 669–676. https://doi.org/10.3899/jrheum.200367
Krajewska-Włodarczyk, M., Szeląg, M., Batko, B., Żuber, Z., Orleański, M., Podwójcic, K., Sowiński, J., Jopek, J., Świderek, M., Maluchnik, M., Brzosko, M., Śmiglewska, A., & Kwiatkowska, B. (2024). Rheumatoid arthritis epidemiology: A nationwide study in Poland. Rheumatology International, 44(6), 1155–1163. https://doi.org/10.1007/s00296-024-05591-8
Galloway, J., Capron, J. P., De Leonardis, F., Fakhouri, W., Rose, A., Kouris, I., & Burke, T. (2020). The impact of disease severity and duration on cost, early retirement, and ability to work in rheumatoid arthritis in Europe: An economic modelling study. Rheumatology Advances in Practice, 4(2), Article rkaa041. https://doi.org/10.1093/rap/rkaa041
Studenic, P., Aletaha, D., de Wit, M., Stamm, T. A., Alasti, F., Lacaille, D., Smolen, J. S., & Felson, D. T. (2023). American College of Rheumatology/EULAR remission criteria for rheumatoid arthritis: 2022 revision. Arthritis & Rheumatology, 75(1), 15–22. https://doi.org/10.1002/art.42347
Boissier, M. C., Biton, J., Semerano, L., Decker, P., & Bessis, N. (2020). Origins of rheumatoid arthritis. Joint Bone Spine, 87(4), 301–306. https://doi.org/10.1016/j.jbspin.2019.11.009
Ishikawa, Y., & Terao, C. (2020). The impact of cigarette smoking on risk of rheumatoid arthritis: A narrative review. Cells, 9(2), Article 475. https://doi.org/10.3390/cells9020475
Adami, G., Viapiana, O., Rossini, M., Orsolini, G., Bertoldo, E., Giollo, A., Gatti, D., & Fassio, A. (2021). Association between environmental air pollution and rheumatoid arthritis flares. Rheumatology, 60(10), 4591–4597. https://doi.org/10.1093/rheumatology/keab049
Scherer, H. U., Häupl, T., & Burmester, G. R. (2020). The etiology of rheumatoid arthritis. Journal of Autoimmunity, 110, Article 102400. https://doi.org/10.1016/j.jaut.2019.102400
Weyand, C. M., & Goronzy, J. J. (2021). The immunology of rheumatoid arthritis. Nature Immunology, 22(1), 10–18. https://doi.org/10.1038/s41590-020-00816-x
Bobek, D., Banić Stipetić, A., Franić, M., Lucijanić, M., Lucijanić, J., Gudelj Gračanin, A., Mijačika, L., & Perić, P. (2022). Use of non-steroidal anti-inflammatory drugs in patients with advanced active rheumatoid arthritis. Acta Clinica Croatica, 61(4), 588–598. https://doi.org/10.20471/acc.2022.61.04.04
Ghlichloo, I., & Gerriets, V. (2023). Nonsteroidal anti-inflammatory drugs (NSAIDs). In StatPearls. StatPearls Publishing.
Delteil, A., Lambert, C., Pereira, B., Couderc, M., Malochet-Guinamand, S., Pickering, M. E., Villedon, M., Mathieu, S., Soubrier, M., & Tournadre, A. (2023). Glucocorticoid trajectories over 2 years in patients with rheumatoid arthritis in a real-life setting. RMD Open, 9(4), Article e003366. https://doi.org/10.1136/rmdopen-2023-003366
Smolen, J. S., Landewé, R. B. M., Bergstra, S. A., Kerschbaumer, A., Sepriano, A., Aletaha, D., Caporali, R., Edwards, C. J., Hyrich, K. L., Pope, J. E., de Souza, S., Stamm, T. A., Takeuchi, T., Verschueren, P., Winthrop, K. L., Balsa, A., Bathon, J. M., Buch, M. H., Burmester, G. R., Buttgereit, F., . . . van der Heijde, D. (2023). EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update. Annals of the Rheumatic Diseases, 82(1), 3–18. https://doi.org/10.1136/ard-2022-223356
Hua, L., Du, H., Ying, M., Wu, H., Fan, J., & Shi, X. (2020). Efficacy and safety of low-dose glucocorticoids combined with methotrexate and hydroxychloroquine in the treatment of early rheumatoid arthritis: A single-center, randomized, double-blind clinical trial. Medicine, 99(27), Article e20824. https://doi.org/10.1097/MD.0000000000020824
Fraenkel, L., Bathon, J. M., England, B. R., St Clair, E. W., Arayssi, T., Carandang, K., Deane, K. D., Genovese, M., Huston, K. K., Kerr, G., Kremer, J., Nakamura, M. C., Russell, L. A., Singh, J. A., Smith, B. J., Sparks, J. A., Venkatachalam, S., Weinblatt, M. E., Al-Gibbawi, M., Baker, J. F., . . . Akl, E. A. (2021). 2021 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis & Rheumatology, 73(7), 1108–1123. https://doi.org/10.1002/art.41752
Roubille, C., Coffy, A., Rincheval, N., Dougados, M., Flipo, R. M., Daurès, J. P., & Combe, B. (2021). Ten-year analysis of the risk of severe outcomes related to low-dose glucocorticoids in early rheumatoid arthritis. Rheumatology, 60(8), 3738–3746. https://doi.org/10.1093/rheumatology/keaa850
Pujades-Rodriguez, M., Morgan, A. W., Cubbon, R. M., & Wu, J. (2020). Dose-dependent oral glucocorticoid cardiovascular risks in people with immune-mediated inflammatory diseases: A population-based cohort study. PLOS Medicine, 17(12), Article e1003432. https://doi.org/10.1371/journal.pmed.1003432
Santiago, T., Voshaar, M., de Wit, M., Carvalho, P. D., Buttgereit, F., Cutolo, M., Paolino, S., Castelar Pinheiro, G. R., Boers, M., & Da Silva, J. A. P. (2021). Patients’ and rheumatologists’ perspectives on the efficacy and safety of low-dose glucocorticoids in rheumatoid arthritis—An international survey within the GLORIA study. Rheumatology, 60(7), 3334–3342. https://doi.org/10.1093/rheumatology/keaa785
Cronstein, B. N., & Aune, T. M. (2020). Methotrexate and its mechanisms of action in inflammatory arthritis. Nature Reviews Rheumatology, 16(3), 145–154. https://doi.org/10.1038/s41584-020-0373-9
Chatzidionysiou, K., & Sfikakis, P. P. (2019). Low rates of remission with methotrexate monotherapy in rheumatoid arthritis: Review of randomised controlled trials could point towards a paradigm shift. RMD Open, 5(2), Article e000993. https://doi.org/10.1136/rmdopen-2019-000993
Tan, J. M., Reeve, E., Fraser, L., Proudman, S. M., & Wiese, M. D. (2023). Barriers and enablers in the use of parenteral methotrexate in rheumatoid arthritis patients: A scoping review. Arthritis Care & Research, 75(11), 2306–2315. https://doi.org/10.1002/acr.25141
Tanaka, Y. (2023). Subcutaneous injection of methotrexate: Advantages in the treatment of rheumatoid arthritis. Modern Rheumatology, 33(4), 633–639. https://doi.org/10.1093/mr/roac156
Padda, I. S., & Goyal, A. (2023). Leflunomide. In StatPearls. StatPearls Publishing.
Choi, J., Patel, P., & Fenando, A. (2024). Sulfasalazine. In StatPearls. StatPearls Publishing.
Nirk, E. L., Reggiori, F., & Mauthe, M. (2020). Hydroxychloroquine in rheumatic autoimmune disorders and beyond. EMBO Molecular Medicine, 12(8), Article e12476. https://doi.org/10.15252/emmm.202012476
Rempenault, C., Combe, B., Barnetche, T., Gaujoux-Viala, C., Lukas, C., Morel, J., & Hua, C. (2018). Metabolic and cardiovascular benefits of hydroxychloroquine in patients with rheumatoid arthritis: A systematic review and meta-analysis. Annals of the Rheumatic Diseases, 77(1), 98–103. https://doi.org/10.1136/annrheumdis-2017-211836
Mitoma, H., Horiuchi, T., Tsukamoto, H., & Ueda, N. (2018). Molecular mechanisms of action of anti-TNF-α agents: Comparison among therapeutic TNF-α antagonists. Cytokine, 101, 56–63. https://doi.org/10.1016/j.cyto.2016.08.014
Rubbert-Roth, A., Szabó, M. Z., Kedves, M., Nagy, G., Atzeni, F., & Sarzi-Puttini, P. (2019). Failure of anti-TNF treatment in patients with rheumatoid arthritis: The pros and cons of the early use of alternative biological agents. Autoimmunity Reviews, 18(12), Article 102398. https://doi.org/10.1016/j.autrev.2019.102398
Favalli, E. G. (2020). Understanding the role of interleukin-6 (IL-6) in the joint and beyond: A comprehensive review of IL-6 inhibition for the management of rheumatoid arthritis. Rheumatology and Therapy, 7(3), 473–516. https://doi.org/10.1007/s40744-020-00219-2
Pablos, J. L., Navarro, F., Blanco, F. J., Román-Ivorra, J. A., Alonso, A., Martín Mola, E., Cantalejo, M., Ercole, L., Rivero, N., & Study Investigators. (2019). Efficacy of tocilizumab monotherapy after response to combined tocilizumab and methotrexate in patients with rheumatoid arthritis: The randomised JUST-ACT study. Clinical and Experimental Rheumatology, 37(3), 437–444.
Burmester, G. R., Strand, V., Kivitz, A. J., Hu, C. C., Wang, S., van Hoogstraten, H., Klier, G. L., & Fleischmann, R. (2023). Long-term safety and efficacy of sarilumab with or without background csDMARDs in rheumatoid arthritis. Rheumatology, 62(10), 3268–3279. https://doi.org/10.1093/rheumatology/kead062
Ramírez, J., & Cañete, J. D. (2018). Anakinra for the treatment of rheumatoid arthritis: A safety evaluation. Expert Opinion on Drug Safety, 17(7), 727–732. https://doi.org/10.1080/14740338.2018.1486819
Tavakolpour, S., Alesaeidi, S., Darvishi, M., GhasemiAdl, M., Darabi-Monadi, S., Akhlaghdoust, M., Elikaei Behjati, S., & Jafarieh, A. (2019). A comprehensive review of rituximab therapy in rheumatoid arthritis patients. Clinical Rheumatology, 38(11), 2977–2994. https://doi.org/10.1007/s10067-019-04699-8
Genovese, M. C., Pacheco-Tena, C., Covarrubias, A., Leon, G., Mysler, E., Keiserman, M., Valente, R. M., Nash, P., Simon-Campos, J. A., Box, J., Legerton, C. W., III, Nasonov, E., Durez, P., Elegbe, A., Wong, R., Li, X., Banerjee, S., & Alten, R. (2018). Long-term safety and efficacy of subcutaneous abatacept in patients with rheumatoid arthritis: 5-year results from a phase IIIb trial. The Journal of Rheumatology, 45(8), 1085–1092. https://doi.org/10.3899/jrheum.170344
Conran, C. A., & Moreland, L. W. (2022). A review of biosimilars for rheumatoid arthritis. Current Opinion in Pharmacology, 64, Article 102234. https://doi.org/10.1016/j.coph.2022.102234
Mehta, P., & Manson, J. J. (2020). What is the clinical relevance of TNF inhibitor immunogenicity in the management of patients with rheumatoid arthritis? Frontiers in Immunology, 11, Article 589. https://doi.org/10.3389/fimmu.2020.00589
Min, H. K., Kim, S. H., Kim, H. R., & Lee, S. H. (2022). Therapeutic utility and adverse effects of biologic disease-modifying anti-rheumatic drugs in inflammatory arthritis. International Journal of Molecular Sciences, 23(22), Article 13913. https://doi.org/10.3390/ijms232213913
Tanaka, Y., Luo, Y., O’Shea, J. J., & Nakayamada, S. (2022). Janus kinase-targeting therapies in rheumatology: A mechanisms-based approach. Nature Reviews Rheumatology, 18(3), 133–145. https://doi.org/10.1038/s41584-021-00726-8
Taylor, P. C., Choy, E., Baraliakos, X., Szekanecz, Z., Xavier, R. M., Isaacs, J. D., Strengholt, S., Parmentier, J. M., Lippe, R., & Tanaka, Y. (2024). Differential properties of Janus kinase inhibitors in the treatment of immune-mediated inflammatory diseases. Rheumatology, 63(2), 298–308. https://doi.org/10.1093/rheumatology/kead448
Angelini, J., Talotta, R., Roncato, R., Fornasier, G., Barbiero, G., Dal Cin, L., Brancati, S., & Scaglione, F. (2020). JAK inhibitors for the treatment of rheumatoid arthritis: A focus on the present and an outlook on the future. Biomolecules, 10(7), Article 1002. https://doi.org/10.3390/biom10071002
Nash, P., Kerschbaumer, A., Dörner, T., Dougados, M., Fleischmann, R. M., Geissler, K., McInnes, I., Pope, J. E., van der Heijde, D., Stoffer-Marx, M., Takeuchi, T., Trauner, M., Winthrop, K. L., de Wit, M., Aletaha, D., Baraliakos, X., Boehncke, W. H., Emery, P., Isaacs, J. D., Kremer, J., . . . Smolen, J. S. (2021). Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: A consensus statement. Annals of the Rheumatic Diseases, 80(1), 71–87. https://doi.org/10.1136/annrheumdis-2020-218398
Cohen, S. B., van Vollenhoven, R. F., Winthrop, K. L., Zerbini, C. A. F., Tanaka, Y., Bessette, L., Zhang, Y., Khan, N., Hendrickson, B., Enejosa, J. V., & Burmester, G. R. (2021). Safety profile of upadacitinib in rheumatoid arthritis: Integrated analysis from the SELECT phase III clinical programme. Annals of the Rheumatic Diseases, 80(3), 304–311. https://doi.org/10.1136/annrheumdis-2020-218510
Cohen, S. B., Tanaka, Y., Mariette, X., Curtis, J. R., Lee, E. B., Nash, P., Winthrop, K. L., Charles-Schoeman, C., Wang, L., Chen, C., Kwok, K., Biswas, P., Shapiro, A., Madsen, A., & Wollenhaupt, J. (2020). Long-term safety of tofacitinib up to 9.5 years: A comprehensive integrated analysis of the rheumatoid arthritis clinical development programme. RMD Open, 6(3), Article e001395. https://doi.org/10.1136/rmdopen-2020-001395
Harrington, R., Harkins, P., & Conway, R. (2023). Janus kinase inhibitors in rheumatoid arthritis: An update on the efficacy and safety of tofacitinib, baricitinib, and upadacitinib. Journal of Clinical Medicine, 12(20), Article 6690. https://doi.org/10.3390/jcm12206690
Ytterberg, S. R., Bhatt, D. L., Mikuls, T. R., Koch, G. G., Fleischmann, R., Rivas, J. L., Germino, R., Menon, S., Sun, Y., Wang, C., Shapiro, A. B., Kanik, K. S., Connell, C. A., & ORAL Surveillance Investigators. (2022). Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis. The New England Journal of Medicine, 386(4), 316–326. https://doi.org/10.1056/NEJMoa2109927
Balanescu, A. R., Citera, G., Pascual-Ramos, V., Bhatt, D. L., Connell, C. A., Gold, D., Chen, A. S., Sawyerr, G., Shapiro, A. B., Pope, J. E., & Schulze-Koops, H. (2022). Infections in patients with rheumatoid arthritis receiving tofacitinib versus tumour necrosis factor inhibitors: Results from the open-label, randomised controlled ORAL Surveillance trial. Annals of the Rheumatic Diseases, 81(11), 1491–1503. https://doi.org/10.1136/ard-2022-222405
Ramiro, S., Landewé, R. B., van der Heijde, D., Sepriano, A., FitzGerald, O., Ostergaard, M., Homik, J., Elkayam, O., Thorne, J. C., Larche, M., Ferraccioli, G., Backhaus, M., Boire, G., Combe, B., Schaeverbeke, T., Saraux, A., Dougados, M., Rossini, M., Govoni, M., Sinigaglia, L., . . . Maksymowych, W. P. (2020). Is treat-to-target really working in rheumatoid arthritis? A longitudinal analysis of a cohort of patients treated in daily practice (RA BIODAM). Annals of the Rheumatic Diseases, 79(4), 453–459. https://doi.org/10.1136/annrheumdis-2019-216819
Hidayat, R., Fauzia, F., Parlindungan, F., Wibowo, S. A. K., Ariane, A., Damanik, J., & Araminta, A. P. (2024). Predictive factors of methotrexate monotherapy success in patients with rheumatoid arthritis in a national referral center: A cohort study. BMC Rheumatology, 8(1), Article 42. https://doi.org/10.1186/s41927-024-00412-8
Kjørholt, K. E., Sundlisæter, N. P., Aga, A. B., Sexton, J., Olsen, I. C., Fremstad, H., Spada, C., Madland, T. M., Høili, C. A., Bakland, G., Lexberg, Å., Hansen, I. J. W., Hansen, I. M., Haukeland, H., Ljoså, M. A., Moholt, E., Uhlig, T., Kvien, T. K., Solomon, D. H., van der Heijde, D., . . . Lillegraven, S. (2024). Effects of tapering conventional synthetic disease-modifying antirheumatic drugs to drug-free remission versus stable treatment in rheumatoid arthritis (ARCTIC REWIND): 3-year results from an open-label, randomised controlled, non-inferiority trial. The Lancet Rheumatology, 6(5), e268–e278. https://doi.org/10.1016/S2665-9913(24)00021-3
Roodenrijs, N. M. T., Kedves, M., Hamar, A., Nagy, G., van Laar, J. M., van der Heijde, D., & Welsing, P. M. J. (2021). Diagnostic issues in difficult-to-treat rheumatoid arthritis: A systematic literature review informing the EULAR recommendations for the management of difficult-to-treat rheumatoid arthritis. RMD Open, 7(1), Article e001511. https://doi.org/10.1136/rmdopen-2020-001511
Nagy, G., Roodenrijs, N. M. T., Welsing, P. M., Kedves, M., Hamar, A., van der Goes, M. C., Kent, A., Bakkers, M., Blaas, E., Senolt, L., Szekanecz, Z., Choy, E., Dougados, M., Jacobs, J. W., Geenen, R., Bijlsma, H. W., Zink, A., Aletaha, D., Schoneveld, L., van Riel, P., . . . van Laar, J. M. (2021). EULAR definition of difficult-to-treat rheumatoid arthritis. Annals of the Rheumatic Diseases, 80(1), 31–35. https://doi.org/10.1136/annrheumdis-2020-217344
Roodenrijs, N. M. T., Welsing, P. M. J., van Roon, J., Schoneveld, J. L. M., van der Goes, M. C., Nagy, G., Townsend, M. J., & van Laar, J. M. (2022). Mechanisms underlying DMARD inefficacy in difficult-to-treat rheumatoid arthritis: A narrative review with systematic literature search. Rheumatology, 61(9), 3552–3566. https://doi.org/10.1093/rheumatology/keac114
Roodenrijs, N. M. T., Hamar, A., Kedves, M., Nagy, G., van Laar, J. M., van der Heijde, D., & Welsing, P. M. J. (2021). Pharmacological and non-pharmacological therapeutic strategies in difficult-to-treat rheumatoid arthritis: A systematic literature review informing the EULAR recommendations for the management of difficult-to-treat rheumatoid arthritis. RMD Open, 7(1), Article e001512. https://doi.org/10.1136/rmdopen-2020-001512
Downloads
Published
Issue
Section
License
Copyright (c) 2026 Karolina Wołk, Magdalena Bartold, Maria Irena Grys, Filip Kochański, Janina Pohrybieniuk, Kamil Rajczyk, Aleksandra Jaskulska, Magda Skudzińska, Jan Pietrzak, Dominika Błonka
This work is licensed under a Creative Commons Attribution 4.0 International License.
All articles are published in open-access and licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0). Hence, authors retain copyright to the content of the articles.
CC BY 4.0 License allows content to be copied, adapted, displayed, distributed, re-published or otherwise re-used for any purpose including for adaptation and commercial use provided the content is attributed.
How to Cite
